Icahn School of Medicine Mount Sinai West and Morningside, 1000 Tenth Avenue, New York, NY 10019, United States of America.
Ruttenberg Treatment Center, Tisch Cancer Institute, 1470 Madison Avenue, 3rd Floor, New York, NY, 10029., United States of America.
Blood Rev. 2023 Jul;60:101070. doi: 10.1016/j.blre.2023.101070. Epub 2023 Mar 5.
Acute lymphoblastic/lymphocytic leukemia (ALL) occurring post-cancer diagnosis (secondary ALL - sALL) is increasingly recognized as a discrete entity, constituting up to as much as 5-10% of all new ALL diagnoses, and carrying its own biologic, prognostic and therapeutic significance. In this review, we will outline the history and current state of research into sALL. We will explore the evidence for differences underlining its existence as a distinct subgroup, as well as examining what might be driving such differences etiologically, including prior chemotherapy. We will examine these distinctions on population-, chromosomal-, and molecular-levels, and we will consider whether they translate to differences in clinical outcome, and whether they do - or should - warrant differences in treatment selection.
癌症诊断后发生的急性淋巴细胞白血病/淋巴细胞白血病（ALL）（继发性 ALL - sALL）越来越被认为是一种独特的实体，占所有新 ALL 诊断的比例高达 5-10%，并具有其自身的生物学、预后和治疗意义。在这篇综述中，我们将概述 sALL 的历史和当前研究状况。我们将探讨支持其作为一个独特亚组存在的证据，以及研究可能导致这种差异的病因学因素，包括先前的化疗。我们将在人群、染色体和分子水平上检查这些差异，并考虑它们是否转化为临床结果的差异，以及它们是否 - 或应该 - 需要在治疗选择上有所区别。
